Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research article
  • Open Access
  • Open Peer Review

NK and NKT cells in the diagnosis of diffuse lung diseases presenting with a lymphocytic alveolitis

BMC Pulmonary Medicine201919:39

https://doi.org/10.1186/s12890-019-0802-1

©  The Author(s). 2019

  • Received: 17 July 2018
  • Accepted: 4 February 2019
  • Published:
Open Peer Review reports

Abstract

Background

Diffuse lung diseases (DLD) are characterized by different immunophenotypes in the bronchoalveolar lavage fluid (BALF). We aimed to evaluate the diagnostic value of BALF NK and NKT cell counts of patients with DLD and lymphocytic alveolitis.

Methods

We assessed 202 patients with DLD, who underwent BALF immunophenotyping. Samples were routinely processed by flow cytometry and lymphocyte subsets were compared between patients with sarcoidosis (n = 106), hypersensitivity pneumonitis (HP; n = 53), and other DLDs (n = 43). We compared absolute counts and percentages of NK and NKT cells between patients with HP versus the remaining DLD patients. To assess the accuracy of BALF lymphocyte subsets in the diagnosis of HP, we calculated the respective areas under the receiver operating characteristic curves (AUC-ROC).

Results

Patients with HP had significantly higher numbers of BALF NK cells, and its percentage was significantly associated with a higher odds of HP, even after adjustment for the NKT and CD8+ cells. For the absolute number of BALF NK cells, we found an AUC-ROC of 0.76 (95%CI = 0.68–0.84) when comparing patients with HP versus the remaining DLD. The cut-offs of 2000 NK cells/mL and of 2.4% NK cells in the BALF had a specificity and a negative predictive value over 80% for the diagnosis of HP. BALF NK cells absolute counts were significantly higher in HP patients with a restrictive pattern. No such differences were observed for NKT cells.

Conclusions

BALF NK immunophenotyping may be a helpful adjunct to the diagnostic work-up of DLD, particularly in the differential diagnosis of HP.

Keywords

  • Bronchoalveolar lavage fluid
  • Diffuse lung diseases
  • Hypersensitivity pneumonitis
  • NKT cells
  • Natural killer cells
  • Sarcoidosis

Background

Diffuse lung diseases (DLD) are a heterogeneous group of disorders, many of them with an unknown etiology, that are characterized by interstitial lung immune/inflammatory cell infiltrates of variable intensity and composition [1, 2]. A multidisciplinary approach is essential for establishing an accurate diagnosis. Analysis of bronchoalveolar lavage fluid (BALF) from the interstitial inflammation is a standardized procedure that is widely available within the diagnostic work up of patients with DLD [2, 3]. Although certain BALF cell profiles have been linked to specific DLDs, they cannot provide a definitive diagnosis [4, 5]. In addition, the diagnostic value of certain cell immunophenotypes, including natural killer (NK) and NKT cells (CD3+ 16/56+ cells), needs to be further evaluated [6–9].

NK cells are innate lymphocytes with a cytotoxic function and an ability to secrete several pro- and anti-inflammatory cytokines [10]. NKT cells, in turn, express features of both NK and T cells, and are able to rapidly produce cytokines, modulate the TH1/TH2 balance, and stimulate, or on the contrary, suppress immune responses [11–13]. There have been recent reports that patients with hypersensitivity pneumonitis (HP) have a higher BALF NKT cells percentage than patients with sarcoidosis and healthy controls [6, 7, 9]. Higher NK and NKT-like cell counts have also been detected in the BALF of patients with organizing pneumonia (OP) compared with those with idiopathic pulmonary fibrosis (IPF) or healthy controls [14, 15]. Deficient or impaired NKT cells function may also have a role in the pathogenesis of sarcoidosis (reviewed in [11]). In brief, although the exact role of BALF NK and NKT cells in DLD has not been fully established, assessment of these cell subtypes by flow cytometry may be a useful supplement for the diagnosis of DLD, particularly as these cells in the lungs have immune regulatory functions and may be involved in the modulation of the bronchoalveolar inflammation [16]. Therefore, the aim of this study was to characterize and compare, using flow cytometry immunophenotyping, BALF NK and NKT cell populations in patients with DLD and lymphocytic alveolitis, evaluating how they relate to their clinical presentations.

Methods

Study population

We prospectively included a total of 202 patients observed at the DLD Outpatient Clinic at Centro Hospitalar de São João, a tertiary referral public hospital in Porto, northern Portugal. All patients having lymphocytic alveolitis (> 15% BALF lymphocytes) detected by BALF differential cell counts within the diagnostic workup of a suspected diffuse lung disease were included; patients with < 15% lymphocytes in BALF were excluded from the analysis. They were assessed using a multidisciplinary diagnostic approach combining clinical, radiologic, and BALF findings (total and differential cell counts and CD4/CD8 ratio) and, in some cases, histopathologic evaluation according to the American Thoracic Society/European Respiratory Society statements [17–20]. The patients were subsequently categorized into 3 groups: a sarcoidosis group, an HP group and an other DLD group. All the patients in the sarcoidosis group fulfilled the European Respiratory Society/American Thoracic Society/World Association of Sarcoidosis and Other Granulomatous Diseases statement on sarcoidosis, and thoracic involvement was classified according to the Scadding criteria [19, 21]. HP was diagnosed using the criteria proposed by Lacasse et al. [22]. In the other DLD group, (i) IPF was diagnosed according to the European Respiratory Society/American Thoracic Society/Japanese Respiratory Society/Latin American Thoracic Society Guidelines; (ii) connective tissue disease with pulmonary involvement (CTD-ILD) diagnosis was based on high-resolution computed tomography (HRCT) findings, BALF features, and a previous CTD diagnosis; and (iii) OP was diagnosed by histologic examination of lung samples obtained by CT-transthoracic lung biopsy [17, 20, 23–25].

Bronchoalveolar lavage fluid and flow cytometry

BALF was obtained within the diagnostic approach of patients on an outpatient basis, in accordance with the technical recommendations of the European Respiratory Society Task Group on BALF [26]. Briefly, the lavage was performed in the subsegmental bronchus of the middle lobe or lingula using 4 × 50 mL saline pre-warmed to 37ºC, with gentle aspiration after each instillation. The last three recovered samples were homogenized and analyzed for total cellular counts (Neubauer chamber) and viability (trypan blue exclusion) determined. A total of 500 cells were counted on Wright-Giemsa stained cytospin slides. The samples were processed by routine flow cytometry analysis in our laboratory with the following monoclonal antibodies combinations in two different tubes - tube 1 contained a combination of anti-CD16-PE (Clone 3G8) (BD Pharmingen, San Diego, CA, USA), anti-CD3-FITC (Clone SK7), anti-CD56-Pe (CloneMY31), anti-CD45-PerCP-Cy5.5 (Clone2D1), and anti-CD19-APC (Clone SJ25C1); tube 2 was prepared with anti-CD4-FITC (Clone SK3), anti-CD8-Pe (Clone SK1), anti-CD45-PerCP-Cy5.5 (Clone2D1), anti-CD3-APC (CloneSK7) (all BD Biosciences, San Jose, CA, USA). The samples were run through a BD FACS Calibur™ flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using BD CellQuest software (BD Biosciences, San Jose, CA, USA), with the acquisition of a minimum of 10,000 total events [27–29]. Lymphocytes were distinguished on the basis of forward (FSC) versus side (SSC) scatters and additional gating was applied using SSC versus CD45 to distinguish between leukocyte populations (namely lymphocytes) and cell debris. Subsequently, we applied SSC versus CD3, CD19 and CD16/56, in order to respectively identify T lymphocytes, B lymphocytes, and NK cells. T lymphocytes were gated based on SSC versus CD3, with T lymphocytes subpopulations being identified as CD3+CD4+ (T-helper) and CD3+CD8+ (T-cytotoxic) cells. B lymphocytes were gated based on SSC versus CD19. Finally, we applied CD3 versus CD16/56 markers to identify NK (CD3− 16/56+ cells) and NKT cells (CD3+ 16/56+) (gating strategy depicted in Additional file 1). All aforementioned cell populations were scored as percentages of lymphocytes. Lymphocyte subpopulations in a parallel peripheral blood sample were analyzed in a similar fashion.

Statistical analysis

Results are presented as means and standard deviations (SD) or as medians and quartiles (percentile 25 and percentile 75) for continuous variables, and as absolute frequencies and proportions for categorical variables. The Mann-Whitney U-test, Kruskal-Wallis test and Chi-squared test were used as appropriate.

Percentages and absolute counts of the different BALF cell subpopulations were compared among participants with HP, sarcoidosis and other DLD. Additionally, we performed a logistic regression to compare participants with a diagnosis of HP with the remaining patients over the percentage and number of each lymphocyte subpopulation (NK, NKT and CD8+ cells) in BALF – after performing an univariable analysis, we performed a multivariable analysis, adjusting the values for each lymphocyte subpopulation for the other subpopulations. We also performed a similar analysis with the diagnosis of sarcoidosis as dependent variable. Associations are presented as odds ratios (ORs) with 95% confidence intervals.

Moreover, we assessed the validity of the percentage and number of each BALF lymphocyte subpopulation in the diagnosis of HP versus the remaining DLD, by assessing the respective area under (AUC) the receiver operating characteristic (ROC) curves. Sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) were calculated for the different NK, NKT and CD8+ BALF lymphocytes cut-offs. The Youden index (J = max [sensitivity+specificity-1]) was used to establish the best cut-off for HP diagnosis. A similar analysis was performed aiming to test each BALF lymphocyte subpopulation in the diagnosis of sarcoidosis versus the remaining DLD.

Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 21.0 (SPSS Inc., Chicago, IL, USA). A p value of less than 0.05 was considered statistically significant. When performing several pairwise comparisons on the same variable, a Bonferroni correction for the p-value was adopted.

Results

From the 202 subjects enrolled, most had a final diagnosis of sarcoidosis (n = 106; 52.5%), followed by HP (n = 53; 26.2%) and other DLD (n = 43; 21.3%). In the other DLD group there were 25 patients with CTD-ILD, 10 with OP, and 8 with IPF. The patients had a mean (SD) age of 46.8 (15.8) years; 41.6% were male and 74.8% were non-smokers. The demographic and BALF characteristics of the different groups are shown in Table 1. All the patients except those with sarcoidosis had mixed alveolitis. Median BALF lymphocytosis was 41.8%, and patients with HP had significantly higher lymphocytosis than those with sarcoidosis (53.2% vs 39.9%, respectively; p < 0.001) or other DLD (53.2% vs 31.2%; p < 0.001). Except for NKT and B cells, we found significant differences regarding the cell percentages of the different BALF lymphocyte subsets across different interstitial lung diseases (Table 2). The percentage of BALF NK cells was significantly higher in patients with HP than in those with sarcoidosis (2.3% vs 1.3%; p < 0.001), or other DLD (2.3% vs 1.0%; p < 0.001) (Fig. 1). A similar pattern was found for the absolute numbers of BALF NK cells (Additional file 2), for which the median count was higher in the HP group than for in the other DLD group (2453 vs 532 cells/mL; p < 0.001).
Table 1

Demographics and bronchoalveolar lavage fluid characteristics of patients with diffuse lung diseases (DLD) by diagnosis

 

All patients (n = 202)

Sarcoidosis (n = 106)

Hypersensitivity pneumonitis (n = 53)

Other DLDs

All (n = 43)

Organising pneumonia (n = 10)

Pulmonary involvement in connective tissue diseases (n = 25)

Idiopathic pulmonary fibrosis (n = 8)

Age, years (mean ± SD)*

46.8 ± 15.8

38.7 ± 11.2

51.3 ± 16.3

61.5 ± 12.0

57.9 ± 11.4

59.1 ± 11.3

73.4 ± 8.2

Gender (female/male)†

118/84

60/46

32/21

26/17

5/5

20/5

1/7

Smoking status (no/yes)†† a

151/48

78/26

44/9

29/13

7/2

20/5

2/6

Total cell count b, ×105cells/mL (median, P25-P75)**

1.7 (0.9–3.3)

1.6 (0.8–2.8)

2.8 (1.2–6.1)

1.4 (0.8–2.4)

1.6 (0.7–2.4)

1.2 (0.8–2.5)

1.5 (1.0–3.6)

Neutrophils b,% (median, P25-P75)*

2.8 (1.2–5.8)

1.6 (1.0–3.0)

4.8 (2.7–8.2)

5.8 (2.4–9.8)

8.7 (5.0–9.9)

3.6 (1.5–9.8)

7.2 (4.7–16.5)

Eosinophils b, % (median, P25-P75)*

0.6 (0.2–2.0)

0.4 (0.1–1.0)

1.6 (0.5–3.7)

0.8 (0.2–2.8)

1.6 (0.4–6.5)

0.4 (0.0–1.5)

2.5 (1.1–8.7)

Alveolar macrophages b, % (median, P25-P75)*

49.2 (34.6–65.2)

56.0 (37.6–68.7)

32.4 (22.9–49.0)

55.2 (42.0–66.4)

44.1 (28.1–58.2)

55.8 (43.3–68.2)

58.6 (44.7–65.3)

Lymphocytes b, % (median, P25-P75)*

41.8 (28.0–57.4)

39.9 (23.9–56.6)

53.2 (41.0–69.1)

31.2 (23.8–43.8)

42.3 (27.6–57.1)

30.0 (23.7–44.8)

26.8 (20.1–33.0)

SD standard-deviation, P percentile

*p < 0.001 for the comparison between sarcoidosis, hypersensitivity pneumonitis and all other DLD (Kruskal-Wallis test); †p = 0.302 for the comparison between sarcoidosis, hypersensitivity pneumonitis and all other DLD (chi-square test); ††p = 0.274 for the comparison between sarcoidosis, hypersensitivity pneumonitis and all other DLD (chi-square test); **p = 0.001 for comparison between sarcoidosis, hypersensitivity pneumonitis and all other DLD (Kruskal-Wallis test)

aNo information for 3 patients – 2 with sarcoidosis and 1 with organizing pneumonia

bNumbers obtained from microscopic counting

Table 2

Percentages of lymphocyte subsets in bronchoalveolar lavage fluid of patients with diffuse lung diseases (DLD)

Median percentage (P25-P75)

All patients (n = 202)

Sarcoidosis (n = 106)

Hypersensitivity pneumonitis (n = 53)

Other DLDs

All (n = 43)

Organising pneumonia (n = 10)

Pulmonary involvement in connective tissue diseases (n = 25)

Idiopathic pulmonary fibrosis (n = 8)

T lymphocytes*

92.5 (87.5–95.9)

94.1 (90.0–96.4)

88.1 (83.0–92.9)

93.5 (87.2–96.6)

93.1 (86.0–95.4)

93.7 (88.8–96.7)

93.7 (87.4–96.9)

CD4+ T cells*

69.5 (46.8–82.3)

77.8 (67.5–84.7)

54.0 (36.0–73.8)

51.6 (29.3–71.9)

45.7 (30.7–68.8)

55.0 (38.3–72.1)

37.1 (25.0–80.2)

CD8+ T cells*

24.9 (13.2–48.4)

18.1 (11.9–28.6)

39.1 (21.2–57.8)

46.8 (24.8–65.7)

50.4 (24.9–64.8)

40.8 (24.2–58.3)

56.8 (18.2–72.7)

CD4/CD8 ratio*

2.8 (1.0–6.3)

4.3 (2.4–7.1)

1.4 (0.6–3.5)

1.1 (0.5–2.9)

0.9 (0.5–2.8)

1.4 (0.7–3.0)

0.7 (0.3–5.2)

NK cells*

1.5 (0.8–2.6)

1.3 (0.6–2.1)

2.3 (1.4–6.5)

1.0 (0.5–2.0)

0.9 (0.3–1.3)

1.1 (0.6–2.1)

1.2 (0.7–4.1)

NKT cells†

2.9 (1.3–6.4)

2.8 (1.4–5.6)

3.8 (1.7–8.2)

2.7 (1.1–6.4)

2.9 (1.2–8.5)

2.6 (1.0–6.5)

2.2 (0.8–5.3)

B lymphocytes**

0.3 (0.1–0.8)

0.3 (0.1–0.7)

0.6 (0.2–1.1)

0.4 (0.1–1.1)

0.4 (0.2–0.8)

1.0 (0.2–1.6)

0.2 (0.1–0.5)

P percentile

*p < 0.001 for the comparison between sarcoidosis, hypersensitivity pneumonitis, and all other DLDs (Kruskal-Wallis test); †p = 0.188 for the comparison between sarcoidosis, hypersensitivity pneumonitis, and all other DLDs (Kruskal-Wallis test); **p = 0.266 for the comparison between sarcoidosis, hypersensitivity pneumonitis, and all other DLDs (Kruskal-Wallis test)

Fig. 1
Fig. 1

Bronchoalveolar lavage fluid (BALF) NK cells (%) in patients with diffuse lung diseases (DLDs). NK cell levels were significantly higher in patients with hypersensitivity pneumonitis compared with patients with sarcoidosis (p < 0.001) and other DLDs (p < 0.001). White circles represent mild outliers and stars represent extreme outliers (two extreme outliers in the hypersensitivity pneumonitis group - 42.5 and 22.9% - are not represented)

In the HP group, the median absolute number of BALF NK cells was significantly higher in patients with a restrictive pattern in lung function tests (n = 23; 6687 cells/mL) than in those with an obstructive pattern (n = 13; 903 cells/mL) or normal lung function (n = 13; 1683 cells/mL) (p < 0.001). We also observed a trend for higher BALF NK cells absolute numbers in HP patients with an acute/subacute (n = 16) versus a chronic (n = 27) clinical presentation (9520 vs 1962 cells/mL, respectively; p = 0.059).

On the other hand, in patients with sarcoidosis, the median absolute number of BALF NK cells was not significantly different between patients with a restrictive pattern (n = 17; 688 cells/mL), an obstructive pattern (n = 25; 613 cells/mL) or normal lung function (n = 48; 836 cells/mL) (p = 0.676). Accordingly, no significant differences were observed when comparing the median absolute number of BALF NK cells across different radiologic stages of sarcoidosis – stage I (n = 33; 688.2 cells/mL); stage II (n = 58; 768.4 cells/mL); stage III/IV (n = 7; 836.2 cells/mL) (p = 0.941) –, as well as when comparing patients in which sarcoidosis resolved (n = 38; 728.9 cells/mL) versus those in which sarcoidosis evolved to a chronic condition (n = 40; 935.5 cells/mL) (p = 0.873). Similar results are obtained when assessing the percentage of NK cells in BALF. No significant differences were observed when comparing the absolute numbers or the percentages of NKT cells in sarcoidosis patients regarding the disease pattern, radiologic stage or evolution.

In the logistic regression, HP diagnosis was established as the dependent variable, while percentages of BALF NK, NKT and CD8+ cells were tested as independent variables. After adjusting for the percentage of NKT and CD8+ cells, the percentage of NK cells was significantly associated with a higher probability of having a diagnosis of HP (OR = 1.29 per each 1% increase in the percentage of NK cells; 95%CI = 1.14–1.45; p < 0.001). The CD8+ cell percentage was also significantly associated with an HP diagnosis, even after adjustment for NK and NKT cells (OR = 1.03 per each 1% increase in the percentage of CD8+ cells; 95%CI = 1.01–1.04; p = 0.003) (Table 3A). Similar results were obtained when absolute BALF NK, NKT and CD8+ cell counts were used as independent variables (Table 3A). We obtained similar results when restricting the comparison to HP versus sarcoidosis (Table 3B).
Table 3

Results of univariate and multivariate analyses with hypersensitivity pneumonitis versus other lung diseases

Lymphocyte populations

Crude OR (95%CI)

P value

Adjusted OR (95%CI)

P value

A. Hypersensitivity pneumonitis versus other diffuse lung diseases (sarcoidosis and other diffuse lung diseases)

 CD8+ (%)

1.02 (1.01–1.04)

0.004

1.03 (1.01–1.04)a

0.003

 NK (%)

1.28 (1.14–1.45)

< 0.001

1.29 (1.14–1.46)b

< 0.001

 NKT (%)

1.03 (0.99–1.06)

0.184

1.02 (0.98–1.06)c

0.386

 CD8+ (absolute count)g

1.02 (1.01–1.03)

< 0.001

1.01 (1.00–1.02)d

0.070

 NK (absolute count)g

1.25 (1.12–1.39)

< 0.001

1.15 (1.03–1.29)e

< 0.001

 NKT (absolute count)g

1.08 (1.03–1.13)

0.002

1.02 (0.99–1.06)f

0.241

B. Hypersensitivity pneumonitis versus sarcoidosis

 CD8+ (%)

1.04 (1.03–1.06)

< 0.001

1.05 (1.03–1.07)a

< 0.001

 NK (%)

1.27 (1.11–1.45)

< 0.001

1.29 (1.12–1.49)b

< 0.001

 NKT (%)

1.02 (0.98–1.06)

0.282

1.01 (0.97–1.05)c

0.725

 CD8+ (absolute count)g

1.02 (1.01–1.03)

< 0.001

1.02 (1.00–1.03)d

0.025

 NK (absolute count)g

1.21 (1.09–1.35)

< 0.001

1.12 (1.00–1.25)e

0.055

 NKT (absolute count)g

1.07 (1.02–1.12)

0.007

1.02 (0.98–1.05)f

0.410

C. Sarcoidosis versus all other diffuse lung diseases (hypersensitivity pneumonitis and other diffuse lung diseases)

 CD8+ (%)

0.95 (0.94–0.97)

< 0.001

0.95 (0.93–0.97)a

< 0.001

 NK (%)

0.87 (0.78–0.97)

0.014

0.85 (0.75–0.96)b

0.010

 NKT (%)

0.99 (0.96–1.03)

0.574

1.00 (0.96–1.04)c

0.938

 CD8+ (absolute count)g

0.98 (0.97–0.99)

< 0.001

0.98 (0.97–0.99)d

0.005

 NK (absolute count)g

0.90 (0.83–0.97)

0.007

0.96 (0.90–1.03)e

0.239

 NKT (absolute count)g

0.97 (0.93–1.00)

0.041

0.99 (0.97–1.03)f

0.993

Results of univariate and multivariate analyses with hypersensitivity pneumonitis (versus the other diffuse lung diseases – 3A; and versus sarcoidosis only – 3B) and sarcoidosis (versus the other diffuse lung diseases – 3C) as dependent variables. Absolute numbers and percentages of CD8+, NK, and NKT cells in the bronchoalveolar lavage fluid were assessed as independent variables

CI confidence interval, NK natural killer, OR odds ratio

aadjusted for percentage of NK and NKT cells

badjusted for percentage of CD8+ and NKT cells

cadjusted for percentage of CD8+ and NK cells

dadjusted for absolute number of NK and NKT cells

eadjusted for absolute number of CD8+ and NKT cells

fadjusted for absolute number of CD8+ and NK cells

gOdds ratio and confidence intervals expressed in number of cells/μL

On the other hand, when sarcoidosis was established as the dependent variable, the percentages of BALF NK and CD8+ cells were significantly associated with a lower risk of having a diagnosis of sarcoidosis: adjusted OR = 0.851 per each 1% increase in the percentage of NK cells (95%CI = 0.753–0.963; p = 0.010); and adjusted OR = 0.949 per each 1% increase in the percentage of CD8+ cells (95%CI = 0.932–0.966; p < 0.001) (Table 3C). Similar results were obtained when assessing the absolute number of CD8+ cells.

We evaluated the performance of selected BALF cytotoxic immunophenotypes in the diagnosis of HP, obtaining the respective ROC curves (Fig. 2 and Table 4). The number of NK cells/mL in the BALF presented the best diagnosis performance of selected immunophenotypes (AUC = 0.76; 95%CI = 0.68–0.84), followed by the number of CD8+ cells/mL (AUC = 0.71; 95%CI = 0.63–0.79) (Fig. 2a). For a cut-off of 2000 NK cells/mL in the BALF, the specificity in the diagnosis of HP was of 80%, while the sensitivity was of 49%, with a corresponding PPV of 46% and a NPV of 82%. Alternatively, and using percent values, a cut-off of 2.4% NK cells in the BALF also corresponded to a specificity of 80%, although with a sensitivity of 47%, PPV of 44% and NPV of 81% (Table 5). The maximum Youden index was 1.4% for the NK cell percentage (sensitivity = 77%; specificity = 55%) and 3446 cells/mL for the absolute cell count (sensitivity = 47%; specificity = 92%). The corresponding values for CD8+ cells were 28.7% (sensitivity = 65%; specificity = 61%) and 40,671 cells/mL (sensitivity = 46%; specificity = 88%) (Table 4).
Fig. 2
Fig. 2

Diagnostic performance of bronchoalveolar lavage fluid NK and CD8+ cells in diagnosing hypersensitivity pneumonitis. Receiver operating characteristic (ROC) curves for absolute numbers (a) and percentages (b) of bronchoalveolar lavage fluid NK and CD8+ cells in the diagnosis of hypersensitivity pneumonitis (n = 53) versus all other diffuse lung diseases (sarcoidosis + other diffuse lung diseases) (n = 149)

Table 4

Diagnostic performance of bronchoalveolar lavage fluid NK, NKT and CD8+ cells in diagnosing hypersensitivity pneumonitis

Lymphocyte populations

AUC-ROC (95%CI)

Maximum Youden’s index cut-off

Sensitivity - % (95%CI)

Specificity - % (95%CI)

PPV - % (95%CI)

NPV - % (95%CI)

NK (cells/mL)

0.76 (0.69–0.84)

3446

47 (40–54)

92 (88–96)

68 (62–74)

83 (78–88)

NK (%)

0.70 (0.62–0.79)

1.4

77 (71–83)

55 (48–62)

37 (30–44)

85 (80–90)

NKT (cells/mL)

0.73 (0.65–0.82)

1678

75 (69–81)

65 (58–72)

42 (35–49)

88 (84–93)

NKT (%)

0.58 (0.49–0.68)

6.1

40 (33–47)

88 (84–93)

39 (33–46)

79 (73–85)

CD8+ (cells/mL)

0.71 (0.62–0.80)

40,671

47 (40–54)

88 (84–93)

59 (52–66)

82 (77–87)

CD8+ (%)

0.63 (0.54–0.72)

28.7

65 (58–72)

61 (54–68)

39 (33–46)

84 (79–89)

Areas Under the Receiver Operating Characteristic curves (AUC-ROC) for absolute and relative numbers of NK, NKT and CD8+ cells in the diagnosis of hypersensitivity pneumonitis (n = 53) versus other diffuse lung diseases (sarcoidosis + other diffuse lung diseases) (n = 149). Sensitivities, specificities and predictive values are presented for the cut-off points with the maximum Youden’s indices

CI confidence interval, PPV positive predictive value, NPV negative predictive value

Table 5

Diagnosis of hypersensitivity pneumonitis versus other diffuse lung diseases (sarcoidosis + other diffuse lung diseases)

Percentage of natural killer cells

Percentage of CD8+ cells

Cut-off

Sn - % (95%CI)

Sp - % (95%CI)

Cut-off

Sn - % (95%CI)

Sp - % (95%CI)

0.5

94 (91–97)

21 (15–27)

15

83 (78–88)

32 (26–38)

1.0

84 (79–89)

37 (30–44)

20

78 (72–84)

45 (38–52)

1.5

73 (67–79)

57 (50–64)

25

65 (58–72)

56 (49–63)

2.0

55 (48–62)

73 (67–79)

30

61 (54–68)

63 (56–70)

2.5

45 (38–52)

81 (76–86)

35

57 (50–64)

67 (61–74)

3.0

41 (34–48)

86 (81–91)

40

49 (42–56)

72 (66–78)

3.5

37 (30–44)

88 (84–92)

45

41 (34–48)

77 (71–83)

4.0

33 (27–40)

92 (88–96)

50

35 (28–42)

81 (76–86)

4.5

31 (25–37)

93 (89–97)

55

29 (23–35)

86 (81–91)

5.0

27 (21–33)

93 (89–97)

60

18 (13–23)

87 (82–92)

Absolute number of natural killer cells/mL

Absolute number of CD8+ cells/mL

Cut-off

Sn - % (95%CI)

Sp - % (95%CI)

Cut-off

Sn - % (95%CI)

Sp - % (95%CI)

500

88 (84–92)

50 (43–57)

15,000

61 (54–68)

63 (56–70)

1000

65 (58–72)

65 (58–72)

20,000

55 (48–62)

73 (67–79)

1500

59 (52–66)

74 (68–80)

25,000

53 (46–60)

78 (72–84)

2000

53 (46–60)

78 (72–84)

30,000

49 (42–56)

79 (73–85)

2500

49 (42–56)

86 (81–91)

35,000

47 (40–54)

84 (79–89)

3000

47 (40–54)

91 (87–95)

40,000

47 (40–54)

87 (82–92)

3500

47 (40–54)

92 (88–96)

45,000

45 (38–52)

89 (85–93)

4000

43 (36–50)

94 (91–97)

50,000

41 (34–48)

89 (85–93)

4500

43 (36–50)

94 (91–97)

55,000

33 (27–40)

91 (87–95)

5000

41 (34–48)

95 (92–98)

60,000

33 (27–40)

93 (89–97)

Sensitivities and specificities for different cut-offs for absolute numbers and percentages of CD8+ and natural killer cells in bronchoalveolar lavage fluid

Sn Sensitivity, Sp Specificity

We performed similar analyses regarding the diagnosis of sarcoidosis, but only the BALF percentage and the absolute number of CD8+ showed an acceptable diagnostic performance (i.e., an AUC-ROC significantly different from 0.5). For the BALF percentage of CD8+ cells, the AUC was of 0.76 for ruling out sarcoidosis (95%CI = 0.69–0.82), with the maximum Youden index obtained with 28.7% (sensitivity = 0.68; specificity = 0.76). For the BALF absolute number of CD8+ cells, the AUC was of 0.68 for ruling out sarcoidosis (95%CI = 0.60–0.75), with the maximum Youden index obtained with 38,070 cells/mL (sensitivity = 92%; specificity = 31%).

Analysis of peripheral blood showed no significant differences regarding the median percentages of NK cells (sarcoidosis: 12.9%; HP: 14.9%; other DLD: 12.4%; p = 0.758), NKT cells (sarcoidosis: 4.0%; HP: 3.4%; other DLD: 2.6%; p = 0.088) and CD8+ cells (sarcoidosis: 29.8%; HP: 36.5%; other DLD: 28.0%; p = 0.297) between the different DLD. Nevertheless, when adjusted for the other peripheral blood cell populations, the percentage of CD8+ was significantly associated with higher chances of having HP (OR = 1.03 per 1% increase; 95%CI = 1.00–1.05; p = 0.025), while the percentage of NKT cells was significantly associated with higher chances of having sarcoidosis (OR = 1.07 per 1% increase; 95%CI = 1.01–1.13; p = 0.032). No significant association was found regarding the percentage of any peripheral blood cell population with the pattern of HP, or with the pattern, radiologic stage or evolution of sarcoidosis (data not shown).

Discussion

In this study, absolute and relative BALF NK cell counts were independently and significantly associated with a diagnosis of Hypersensitivity Pneumonitis in a series of patients with DLD and lymphocytic alveolitis. Moreover, absolute counts were associated with restrictive lung function impairment and an acute/subacute clinical presentation. We prospectively enrolled a diverse range of patients with DLD, as BALF profiling is a useful differential diagnostic aid in daily clinical practice [3, 30]. With such a wide spectrum of entities, a combination of lymphocytic alveolitis and elevated NK cell counts may help to discriminate patients with HP from those with other DLD.

Nevertheless, while information on the NK cell counts might be useful on the diagnostic classification of DLD, further research may be needed on the practical role of such counts within a multidisciplinary approach of a patient with DLD; in this instance, future studies should assess the impact of taking into account the number of BALF NK cells in the differential diagnosis of DLD. This is particularly relevant, as some of the differences found (e.g., regarding the percentage of BALF NK cells across different DLD entities) – although significant – do not have a large magnitude, possibly limiting its clinical use. Another important limitation of this study is that our results may only be generalizable to patients with lymphocytic alveolitis (BALF lymphocytes > 15%). Although we investigated the most clinically common DLDs, there was a large proportion of patients with HP in our series due to high levels of exposure to avian proteins (bird fanciers) and molds (indoor home exposure and occupational exposure in the cork industry) in northern Portugal [28, 31]. Most included HP patients had subacute or chronic presentations, as acute presentations are rare in our clinical practice; while a high BALF lymphocytosis is less frequently observed in chronic presentations, these forms - especially with interstitial pneumonias as a usual interstitial pneumonia (UIP) ‘like’ patterns - are the most frequent in our setting. On the other hand, the unexpectedly low frequency of patients with OP in our series results from the fact that, in our DLD center, patients with OP are usually diagnosed through a Computer Tomography-guided transthoracic biopsy and do not perform BALF. Also, in patients with CTD-ILD, BALF is only performed when that are any particular issues related with the differential diagnosis of lung involvement, as this condition is usually diagnosed according to the autoimmune background and characteristic radiological features on HRCT-scan. The eight patients with IPF in our series belong to the minority (approximately 20%) of patients with IPF and increased lymphocytes in BALF. Mild neutrophilia and mild eosinophilia, by contrast, are common BALF findings [20, 32]. Nevertheless, all the patients with IPF were diagnosed according to the 2011 ERS/ATS criteria, which include (i) absence of any environmental exposure suggesting other diagnoses, and (ii) a negative autoimmune panel test associated with a HRCT scan with definitive UIP [20]. In cases of inconsistency (e.g., signs suggestive of UIP on the HRCT scan) and in patients with an adequate clinical condition, a surgical lung biopsy was performed. In any case, all the diagnoses were discussed in a multidisciplinary team setting, blinded to the results of the cytotoxic lymphocyte subsets phenotyped [33, 34].

Although international consensus statements have been published on the classification of idiopathic interstitial pneumonia, standardization of diagnostic guidelines is still lacking for some DLD, such as HP [18, 22]. A number of diagnostic criteria and prediction rules have been proposed for HP, but their diagnostic accuracy has not been sufficiently validated [35–37]. While a higher frequency of NK cells has been reported in HP patients, the diagnostic value of this finding in BALF had not yet been established [6, 7]. To our knowledge, our study is the first to indicate absolute and relative BALF NK cell count cut-offs (2000/mL and 2.4%) with a specificity and NPV of over 80% for the diagnosis of HP.

Concerning NKT cells, our results contrast with previous studies assessing its frequency in BALF [9, 38]. In fact, Tondell et al., found that the association of high values of NKT cells and activated CD8+ cells was more suggestive of HP than sarcoidosis, while Korosec et al. reported a greater fraction of BALF NKT cells (mostly CD8+ lymphocytes) in HP than in sarcoidosis [9, 38]. Both of these studies, however, assessed few HP patients (n = 10 and n = 17, respectively) and only performed a comparative analysis with sarcoidosis.

To our knowledge, the present study is also the first to describe a higher number of NK cells in the BALF of HP patients with acute/subacute forms and with restrictive lung function impairment, further suggesting a role for lung NK cells in the pathogenesis of HP. In fact, while Korosec et al. found no statistically significant differences between HP clinical presentations, only 5 of 17 HP cases were chronic forms [38]. Also, in the study of Papakosta et al., while no differences were found in BALF NK cells between HP acute and subacute forms, none of the 19 studied patients had a chronic presentation [14].

Conventional human NK cells (CD3−CD16/56+) belong to one of the three innate lymphocyte cell families (group 1 ILCs [ILC1s]) that have been increasingly recognized as key players of immune regulation and human pathology (reviewed in [39]). ILCs, which lack antigen-specific T-cell receptors (TCRs), respond to epithelial- or stromal-derived stress signals by producing an array of cytokines profiles that regulate subsequent immune responses. Both conventional NK cells and other ILC1s mainly produce IFN-gamma on activation, with NK cells exhibiting cytotoxic activity mediated by granzymes and perforin in a similar way as CD8+ cytotoxic T cells [40]. In this sense, ILC1s and conventional NK are now considered innate counterparts to type 1 helper (Th1) and cytotoxic T cells that mount a “Th1 / cytotoxic type” immune response independently of antigen recognition [41]. Accordingly, they act as a first line of defense against pathogens and modulate acute and chronic inflammatory disorders in the human lung.

It was also recently shown that human lung-resident NK cells (about 15% of lung leukocytes) are composed of highly differentiated but hypofunctional CD56dim/CD16+ cells (although typically expressing high levels of perforin), possibly circulating between the blood and lung [42]. These findings suggest that, being lung NK cells mainly non-resident lymphocytes, inflammatory pulmonary disorders may be accompanied by differentiation and functional changes of lung NK cells, putatively overcoming the usual suppressive environment of the normal alveolar space [43]. Our results support the hypothesis that pulmonary NK cells play a particular role in the pathogenesis or in the inflammatory response of DLD, namely as we found that, in patients with different DLD, these cell populations have a significantly different frequency in the BALF but not in the peripheral blood. This view is also in line with the results of several experimental models that have shown that the interstitial lung inflammation dynamics seen in HP (resolution or massive fibrosis) are critically influenced and regulated by NK cell activity and their secreted cytokine profiles [44–46].

Conclusions

BALF analysis and immunophenotyping of lung NK cells, with widely available and common technics and reagents, seems particularly helpful in cases of DLD with lymphocytic alveolitis. Our results show that a cut-off of 2.4% for the percentage of CD3− 16/56+ cells in BALF associates with a diagnosis of HP with a specificity of over 80%. While the functional and immunopathological implications of BALF NK cells deserve further research, our results have practical implications, as they indicate that NK immunophenotyping may be a helpful adjunct to the diagnostic workup of DLD, especially in suspected cases of HP where standardized diagnostic criteria are still lacking.

Abbreviations

AUC: 

Area under curve

BALF: 

Bronchoalveolar lavage fluid

CTD-ILD: 

Connective tissue disease with pulmonary involvement

DLD: 

Diffuse lung diseases

ERS/ATS: 

European Respiratory Society/American Thoracic Society

HP: 

Hypersensitivity pneumonitis

HRCT: 

High-resolution computed tomography

IPF: 

Idiopathic pulmonary fibrosis

NK: 

Natural killer

NKT: 

Natural killer T cells

OP: 

Organizing pneumonia

PPV and NPV: 

Positive and negative predictive values

ROC: 

Receiver operating characteristic curve

Declarations

Acknowledgements

The authors would like to thank Maria do Carmo Palmares for helping with the laboratory proceedings and critical review. We are grateful too to all the participants in the multi-disciplinary ILD team, for the evaluation and monitoring of the patients included in this study, namely José Miguel Pereira and Rui Cunha for their radiology assessment and Conceição Souto Moura and Susana Guimarães for their pathology assistance.

Funding

The authors declare that no funding was received for this work.

Availability of data and materials

The datasets used and/or analysed during the current study may be available from the corresponding author on reasonable request.

Authors’ contributions

OS, EP, LD, BS-P and AM elaborated the study conception and design, analysis of data, manuscript preparation and revision. OS and MB performed the laboratory proceedings. EP, NM, PCM and AM assisted the patients in the Interstitial Lung Diseases unit, cooperated in the data acquisition and drafted the manuscript. BS-P e LD participated in the data acquisition and performed the statistic evaluation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The Ethics Committee for Health of São João Hospital (Comissão de Ética para a Saúde – CES; Centro Hospitalar São João) approved this research article (Ethics Reference No: 39/2018). Data had been previously been anonymized and no consent to participate was needed, as validated an Ethics Committee for Health Statement.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Basic & Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, Alameda Professor Hernâni Monteiro, University of Porto, 4200-319 Porto, Portugal
(2)
CINTESIS - Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal
(3)
Department of Pulmonology, Hospital de São João and Faculty of Medicine, University of Porto, Porto, Portugal
(4)
MEDCIDS – Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal

References

  1. Cosgrove G, Schwarz M. Approach to the evaluation and diagnosis of interstitial lung disease. In: Schwarz MIKTE, editor. Interstitial lung disease. 5th ed. Shelton: PMPH-USA; 2011. p. 3–34.Google Scholar
  2. Behr J. Approach to the diagnosis of interstitial lung disease. Clin Chest Med. 2012;33(1):1–10.PubMedView ArticleGoogle Scholar
  3. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14.PubMedView ArticleGoogle Scholar
  4. Couto M, Palmares C, Beltrão M, Neves S, Mota P, Morais A, et al. Integrin α E β 7 (CD103) expression in bronchoalveolar lymphocytes of patients with hypersensitivity pneumonitis. Int Arch Occup Environ Health. 2015;88(2):167–73.PubMedView ArticleGoogle Scholar
  5. Mota PC, Morais A, Palmares C, Beltrão M, Melo N, Santos AC, et al. Diagnostic value of CD103 expression in bronchoalveolar lymphocytes in sarcoidosis. Respir Med. 2012;106(7):1014–20.PubMedView ArticleGoogle Scholar
  6. Semenzato G, Agostini C, Zambello R, Trentin L, Chilosi M, Pizzolo G, et al. Lung T cells in hypersensitivity pneumonitis: phenotypic and functional analyses. J Immunol. 1986;137(4):1164–72.PubMedGoogle Scholar
  7. Trentin L, Zambello R, Marcer G, Gemignani C, Luca M, Masciarelli M, et al. Peripheral blood NK cells in patients with extrinsic allergic alveolitis: phenotype and function. Sarcoidosis. 1986;3(1):47–51.PubMedGoogle Scholar
  8. Tøndell A, Rø A, Åsberg A, Børset M, Moen T, Sue-Chu M. Activated CD8+ T cells and NKT cells in BAL fluid improve diagnostic accuracy in sarcoidosis. Lung. 2014;192(1):133–40.PubMedView ArticleGoogle Scholar
  9. Tøndell A, Rø AD, Børset M, Torolf M, Sue-Chu M. Activated CD8+ T cells and natural killer T cells in bronchoalveolar lavage fluid in hypersensitivity pneumonitis and sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2015;31(4):316–24.PubMedGoogle Scholar
  10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.PubMedView ArticleGoogle Scholar
  11. Rijavec M, Volarevic S, Osolnik K, Kosnik M, Korosec P. Natural killer T cells in pulmonary disorders. Respir Med. 2011;105:S20–S5.PubMedView ArticleGoogle Scholar
  12. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol. 2010;11(3):197–206.PubMedView ArticleGoogle Scholar
  13. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res. 2011;343(1):43–55.PubMedView ArticleGoogle Scholar
  14. Papakosta D, Manika K, Gounari E, Kyriazis G, Kontakiotis T, Spyropoulos G, et al. Bronchoalveolar lavage fluid and blood natural killer and natural killer T-like cells in cryptogenic organizing pneumonia. Respirology. 2014;19(5):748–54.PubMedView ArticleGoogle Scholar
  15. Cottin V, Cordier J-F, editors. Cryptogenic organizing pneumonia. Semin Respir Crit Care Med. 2012;33(5):462–75.Google Scholar
  16. Paget C, Trottein F. Role of type 1 natural killer T cells in pulmonary immunity. Mucosal Immunol. 2013;6(6):1054–67.PubMedView ArticleGoogle Scholar
  17. Travis WD, King TE, Bateman ED, Lynch DA, Capron F, Center D, et al. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.View ArticleGoogle Scholar
  18. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Sarcoidosis So. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.View ArticleGoogle Scholar
  20. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Scadding J. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;2(5261):1165.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Lacasse Y, Selman M, Costabel U, Dalphin J-C, Ando M, Morell F, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003;168(8):952–8.PubMedView ArticleGoogle Scholar
  23. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251–6.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814–24.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689–98.PubMedView ArticleGoogle Scholar
  26. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J. 1989;2(6):561–85.Google Scholar
  27. Smith PA, Kohli LM, Wood KL, Hage CA, Twigg Iii HL, Knox KS. Cytometric analysis of BAL T cells labeled with a standardized antibody cocktail correlates with immunohistochemical staining. Cytometry B Clin Cytom. 2006;70(3):170–8.PubMedView ArticleGoogle Scholar
  28. Morais A, Winck J, Delgado I, Palmares M, Fonseca J, e Sá JM, et al. Suberosis and bird fancier's disease: a comparative study of radiological, functional and bronchoalveolar lavage profiles. J Investig Allergol Clin Immunol. 2004;14(1):26–33.PubMedGoogle Scholar
  29. Silveira P, Palmares MC, Delgado L. Bronchoalveolar lavage : methodology and clinical application [translated from Portuguese]. Rev Port Pneumol. 1997;3(2):155–78.View ArticleGoogle Scholar
  30. Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(11):1043–7.PubMedView ArticleGoogle Scholar
  31. Winck J, Delgado L, Murta R, Lopez M, Marques J. Antigen characterization of major cork moulds in Suberosis (cork worker's pneumonitis) by immunoblotting. Allergy. 2004;59(7):739–45.PubMedView ArticleGoogle Scholar
  32. Pires FS, Mota PC, Melo N, Costa D, Jesus J, Cunha R, et al. Idiopathic pulmonary fibrosis—clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort. Rev Port Pneumol (English Edition). 2013;19(1):19–27.View ArticleGoogle Scholar
  33. Flaherty KR, King TE Jr, Raghu G, Lynch IIIJP, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904–10.PubMedView ArticleGoogle Scholar
  34. Walsh SL, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;4(7):557–65.PubMedView ArticleGoogle Scholar
  35. Lacasse Y, Cormier Y. Hypersensitivity pneumonitis. Orphanet J Rare Dis. 2006;1(1):25.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Lacasse Y, Selman M, Costabel U, Dalphin J-C, Morell F, Erkinjuntti-Pekkanen R, et al. Classification of hypersensitivity pneumonitis. Int Arch Allergy Immunol. 2009;149(2):161–6.PubMedView ArticleGoogle Scholar
  37. Nogueira RM, Novais e Bastos H, Martins N, Delgado L, Morais A, Mota PC. Hypersensitivity pneumonitis: antigen diversity and diseases implications. Pulmonology. 2018; in press. https://doi.org/10.1016/j.pulmoe.2018.07.003.
  38. Korosec P, Osolnik K, Kern I, Silar M, Mohorcic K, Kosnik M. Expansion of pulmonary CD8+ CD56+ natural killer T-cells in hypersensitivity pneumonitis. Chest. 2007;132(4):1291–7.PubMedView ArticleGoogle Scholar
  39. Mjösberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138(5):1265–76.PubMedView ArticleGoogle Scholar
  40. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol. 2016;138(5):1253–64.PubMedView ArticleGoogle Scholar
  41. Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J Allergy Clin Immunol. 2016;138(5):1243–51.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Marquardt N, Kekäläinen E, Chen P, Kvedaraite E, Wilson JN, Ivarsson MA, et al. Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69− CD56dim cells. J Allergy Clin Immunol. 2017;139(4):1321–30.PubMedView ArticleGoogle Scholar
  43. Robinson B, Pinkston P, Crystal RG. Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest. 1984;74(3):942–50.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Jimenez-Alvarez L, Zúñiga J, Gaxiola M, Checa M, Becerril C, Mendoza F, et al. Inflammatory response and dynamics of lung T cell subsets in Th1, Th2 biased and Th2 deficient mice during the development of hypersensitivity pneumonitis. Exp Mol Pathol. 2010;88(3):407–15.PubMedView ArticleGoogle Scholar
  45. Denis M, Bisson D, Ghadirian E. Cellular and cytokine profiles in spontaneous regression phase of hypersensitivity pneumonitis. Exp Lung Res. 1993;19(2):257–71.PubMedView ArticleGoogle Scholar
  46. Denis M. Mouse hypersensitivity pneumonitis: depletion of NK cells abrogates the spontaneous regression phase and leads to massive fibrosis. Exp Lung Res. 1992;18(6):761–73.PubMedView ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us